Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023418 (leukemia)
 93,477 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The antiviral activities of antileukemic drugs 1-beta-D-arabinofuranosylcytosine (Cytarabine; Ara-C), 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine (Ancitabine; Cyclo-C), and N4-behenoyl-1-beta-D-arabinofuranosylcytosine (Enocitabine; BH-AC) were evaluated in vitro against human cytomegalovirus (HCMV) in comparison with those of five other antiviral drugs. Both Ara-C and Cyclo-C showed the strongest inhibitory effect to HCMV. BH-AC inhibited the replication of HCMV and depicted almost as the same dose-response curve as Ganciclovir (DHPG). In the presence of Ara-C, Cyclo-C, or BH-AC, triphosphate forms of the nucleoside analogs were detected in the HCMV-infected cells, and synthesis of HCMV DNA was strongly suppressed. Thus, Ara-C, Cyclo-C, and BH-AC were not only antileukemic, but also antiviral in vitro. However, Ara-C and Cyclo-C may not be suitable as anti-HCMV agents, because they are cytotoxic or excreted rapidly in the urine in vivo [Van Voris, 1984; Hirayama et al., 1974]. Because of lower toxicity and longer retention in vivo, BH-AC may be expected as an anti-HCMV agent in patients with leukemia, in addition to serving as an antileukemic drug.
 ...
PMID:Antiviral effect of antileukemic drugs N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) and 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine (cyclo-C) against human cytomegalovirus. 169 58

We report here a case of acute lymphoblastic leukemia (ALL) which occurred in a 34-year-old female with chronic renal failure (CRF). Although she was placed on chronic hemodialysis therapy (HD), she achieved complete remission (CR) with the use of chemotherapy. Our therapeutic regime was as follows. 1. The full dose of the Japan adult leukemia study group (JALSG)-ALL90 protocol was given and consisted of vincristine, cyclophosphamide, doxorubicin, mitoxantrone and predonisolone at the stage of CRF (serum creatinine concentration equal to/or less than 5.6 mg/dl). 2. The full dose of etoposide and 80% dose of cyclophosphamide, aclarubicin and vindesine used for consolidation therapy may be toxic when they are given after HD. 3. The dose of Enocitabine should be divided in every 12h in the context of toxicity to bone marrow and the mechanism of action. In conclusion, to induce remission in the case of acute lymphoblastic leukemia, we suggest that it is possible to give 80% to a full dose of JALSG-ALL90 protocol, despite the complication of CRF or HD.
 ...
PMID:[A case of acute lymphoblastic leukemia and chronic renal failure resulting in complete remission with chronic hemodialysis]. 760 29